Dexcel Pharma

Executive Summary

Dexcel Pharma is Israel's largest private pharmaceutical company, established in 2020 and employing over 1,000 people. The company develops, manufactures, and commercializes a broad portfolio of branded, OTC, and generic small-molecule drugs, as well as biologics, oligonucleotides, and gene therapies. With state-of-the-art R&D and highly automated oral-solid dosage manufacturing facilities, Dexcel serves key markets including the United States, Germany, the United Kingdom, and Austria. The company's integrated business model and focus on multiple therapeutic areas position it as a versatile player in the global pharmaceutical landscape.

Upcoming Catalysts (preview)

• Q3 2026FDA approval for a new generic or branded product in the US market60% success
• Q4 2026Expansion of manufacturing capacity or strategic partnership in Europe70% success
• H1 2027Launch of a novel oligonucleotide or gene therapy candidate into clinical trials40% success